Zandecki M, Dupriez B, Laï J L, Fenaux P, Facon T, Lepelley P, Estienne M H, Huart J J, Jouet J P
Laboratoire d'Hématologie, Hôpital Calmette, Lille, France.
Nouv Rev Fr Hematol (1978). 1987;29(6):365-9.
Two cases of Burkitt cell leukaemia (ALL3) occurring 60 and 51 months respectively after treatment of Hodgkin's disease (HD) are described. Clinical, cytological, immunological and cytogenetic features in these patients were comparable with those of the 6 previously published cases and with de novo ALL3. The prognosis of these secondary ALL3 is uniformly poor: our 2 patients died 2 and 14 days after the start of combination chemotherapy, and all the other cases survived less than 60 days after diagnosis. The significance of ALL3 occurring after HD is discussed: the association is probably not fortuitous, and its pathogenic mechanisms probably differ from those intervening in secondary myeloid leukaemias.
本文描述了两例霍奇金淋巴瘤(HD)治疗后分别于60个月和51个月发生伯基特细胞白血病(ALL3)的病例。这些患者的临床、细胞学、免疫学和细胞遗传学特征与之前发表的6例病例以及原发性ALL3的特征相当。这些继发性ALL3的预后普遍较差:我们的2例患者在联合化疗开始后2天和14天死亡,所有其他病例在诊断后存活时间均少于60天。文中讨论了HD后发生ALL3的意义:这种关联可能并非偶然,其致病机制可能与继发性髓系白血病不同。